10.46
+0.16(+1.55%)
Currency In USD
| Previous Close | 10.3 |
| Open | 10.4 |
| Day High | 10.54 |
| Day Low | 10.2 |
| 52-Week High | 18.35 |
| 52-Week Low | 7.87 |
| Volume | 71,960 |
| Average Volume | 186,976.1 |
| Market Cap | 150.49M |
| PE | -9.94 |
| EPS | -1.05 |
| Moving Average 50 Days | 9.56 |
| Moving Average 200 Days | 10.2 |
| Change | 0.14 |
If you invested $1000 in Anika Therapeutics, Inc. (ANIK) 10 years ago, it would be worth $282.49 as of February 06, 2026 at a share price of $10.435. Whereas If you bought $1000 worth of Anika Therapeutics, Inc. (ANIK) shares 5 years ago, it would be worth $271.6 as of February 06, 2026 at a share price of $10.435.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anika Therapeutics Announces Leadership Transition
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive OfficerCheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE)
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
GlobeNewswire Inc.
Nov 05, 2025 12:00 PM GMT
BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final module of its Premarket Approval application (P
Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025
GlobeNewswire Inc.
Oct 23, 2025 8:01 PM GMT
BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the